JPRN-UMIN000030936招募中2 期
A randomized phase II study to evaluate efficacy of negative pressure wound therapy on prophylaxis of the incisional hernia after reversal of temporaly diverting stoma - Negative pressure wound therapy on the prophylaxis of the incisional hernia
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 70
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 85years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •severe skin disease
研究者
相似试验
进行中（未招募）
1 期
Evaluation of 2nd or 3rd line treatment by Nivolumab monotherapy or Nivolumab plus Ipilimumab, for unresectable Mesothelioma patientsMalignant Pleural MesotheliomaEUCTR2015-004475-75-FRIFCT114
进行中（未招募）
1 期
A randomized study to explore the efficacy and feasibility of rotations between sunitinib and everolimus versus sequential treatment of sunitinib and everolimus until progression in patients with renal cancer.EUCTR2012-001337-13-ESAPRO115
进行中（未招募）
1 期
A randomized study to explore the efficacy and feasibility of rotations between sunitinib and everolimus versus sequential treatment of sunitinib and everolimus until progression in patients with renal cancer.Metastatic clear cell renal cancerMedDRA version: 14.1Level: LLTClassification code 10038416Term: Renal clear cell carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-001337-13-GRAPRO115
已完成
2 期
A randomized phase II study to explore the efficacy and feasibility of upfront bi-monthly rotations between Everolimus and Pazopanib with sequential treatment of first line Pazopanib and second line Everolimus until progression in patients with advanced or metastatic clear cell renal cancer.10038364Kidney cancerRenal cancerNL-OMON39600Werkgroep Immunotherapie Nederland voor Oncologie100
进行中（未招募）
1 期
A study to investigate if alternating Pazopanib and Everolimus avoids or postpones resistanceEUCTR2011-000127-32-NLWerkgroep Immunotherapie Nederland voor Oncologie100